♥

Neuland Laboratories Limited

ISIN : INE794A01010
NSE : NEULANDLAB
BSE : 524558
Face Value : 10
Industry : Pharmaceuticals & Drugs

EPS : 233.89
EPS (TTM) : 261.94
Price to Earning (P/E) : 51.61
Book Value : 999.07
Price to Bookvalue (P/B) : 12.08
Dividend Yield : 0 %
Return on Equity (ROE) : 26.38 %
Return on Capital Employed (ROCE) : 33.51 %

Neuland Laboratories share price (02-Apr-2026)
National Stock Exchange NSE
Open / Close	0 - 0 NAN %
Low / High	0 - 0 NAN %
Trade Volume	0
52 Week Low / High	0 - 0 NAN %
Bombay Stock Exchange BSE
Open / Close	12425 - 12434.25 0.1 %
Low / High	12080 - 12482.6 3.3 %
Trade Volume	1,082
52 Week Low / High	10598.05 - 19748.4 86.3 %

YOU MAY ALSO LIKE

Stock market course tutorial
Stock Market Investment Course explained in simple words.
Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE
Share Market basics for beginners
Share Market jargons in simple terms
High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE
CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator
How much money do you need to retire
Know how much money do you need to retire, before how much to invest ?

Consolidated Standalone

CONSOLIDATED QUARTERLY RESULT FOR NEULAND LABORATORIES LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	2558.73	2211.7	2937.06	2692.5	4070.73	3629.94	4177.49	3928.28	3850.1	4396.02
Total Income	2565.04	2216.82	2939.45	2701.83	4151.37	3650.33	4207.96	3949.29	3903.67	4444.09
Total Expenditure	2170.04	1925.66	2244.08	2151.67	2872.14	2660.73	2802.61	2715.63	2780.94	3162.42
Other Income	6.32	5.12	2.39	9.33	80.64	20.39	30.48	21.01	53.57	48.07
Operating Profit	395	291.16	695.37	550.16	1279.23	989.6	1405.35	1233.66	1122.73	1281.67
Interest	27.7	28.58	31.75	27.45	42.89	22.14	44.33	37.41	36.09	26.71
Exceptional Items										206.25
PBDT	367.3	262.58	663.62	522.71	1236.34	967.46	1361.02	1196.25	1086.64	1461.21
Depreciation	124.54	127.99	131.72	133.36	134.7	135.86	145.08	151.44	164.63	162.8
Profit Before Tax	242.76	134.59	531.9	389.35	1101.64	831.6	1215.94	1044.81	922.01	1298.41
Tax	24.95	34.93	147.28	83.87	256.2	212.81	323.46	230.91	246.4	319.69
Profit After Tax	217.81	99.66	384.62	305.48	845.44	618.79	892.48	813.9	675.61	978.72
Net Profit	217.81	99.66	384.62	305.48	845.44	618.79	892.48	813.9	675.61	978.72
Equity Capital	129	129	129.01	129.01	129.01	129.01	129.01	129	129.01	129.01
Face Value (IN RS)	10	10	10	10	10	10	10	10	10	10
Calculated EPS	16.88	7.73	29.81	23.68	65.53	47.96	69.18	63.09	52.37	75.86
Diluted Eps After Extraordinary Items	16.97	7.77	29.97	23.81	65.9	48.23	69.56	63.44	52.66	76.28
Diluted Eps Before Extraordinary Items	16.97	7.77	29.97	23.81	65.9	48.23	69.56	63.44	52.66	76.28

STANDALONE QUARTERLY RESULT FOR NEULAND LABORATORIES LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	2558.73	2211.7	2937.06	2692.5	4070.73	3629.94	4177.49	3928.28	3850.1	4396.02
Total Income	2565.04	2216.82	2939.45	2701.83	4151.37	3650.33	4207.96	3949.29	3903.67	4444.09
Total Expenditure	2171.6	1926.92	2245.36	2153.06	2873.56	2657.29	2804.5	2722.64	2782.16	3157.76
Other Income	6.31	5.12	2.39	9.33	80.64	20.39	30.48	21.01	53.57	48.07
Operating Profit	393.44	289.9	694.09	548.77	1277.81	993.04	1403.46	1226.65	1121.51	1286.33
Interest	27.7	28.58	31.75	27.45	42.89	22.14	44.33	37.41	36.09	26.71
Exceptional Items										206.26
PBDT	365.74	261.32	662.34	521.32	1234.92	970.9	1359.13	1189.24	1085.42	1465.88
Depreciation	124.52	127.98	131.72	133.36	134.7	135.86	145.08	151.44	164.62	162.79
Profit Before Tax	241.22	133.34	530.62	387.96	1100.22	835.04	1214.05	1037.8	920.8	1303.09
Tax	22.95	34.93	147.28	83.6	255.12	212.8	323.4	230.79	244.74	319.7
Profit After Tax	218.27	98.41	383.34	304.36	845.1	622.24	890.65	807.01	676.06	983.39
Net Profit	218.27	98.41	383.34	304.36	845.1	622.24	890.65	807.01	676.06	983.39
Equity Capital	129	129	129.01	129.01	129.01	129.01	129.01	129	129.01	129.01
Face Value (IN RS)	10	10	10	10	10	10	10	10	10	10
Calculated EPS	16.92	7.63	29.71	23.59	65.51	48.23	69.04	62.56	52.4	76.23
Diluted Eps After Extraordinary Items	17.01	7.67	29.88	23.72	65.87	48.5	69.42	62.9	52.7	76.65
Diluted Eps Before Extraordinary Items	17.01	7.67	29.88	23.72	65.87	48.5	69.42	62.9	52.7	76.65

Consolidated Standalone

CONSOLIDATED ANNUAL RESULT FOR NEULAND LABORATORIES LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	9510.77	11912	15585.8
Total Income	9531.53	12009.5	15711.2
Total Expenditure	8084.55	9193.56	10959.9
Other Income	20.77	97.48	125.44
Operating Profit	1446.98	2815.9	4751.33
Interest	134.95	130.67	139.97
PBDT	1312.03	2685.23	4611.36
Depreciation	490.4	527.77	597
Profit Before Tax	821.63	2157.46	4014.36
Tax	183.41	522.28	1013.58
Profit After Tax	638.22	1635.18	3000.78
Net Profit	638.22	1635.18	3000.78
Equity Capital	129	129.01	129.01
Face Value (IN RS)	10	10	10
Reserves	8267.61	9803.57	12689.7
Calculated EPS	49.47	126.75	232.6
Diluted Eps After Extraordinary Items	49.74	127.45	233.89
Diluted Eps Before Extraordinary Items	49.74	127.45	233.89

STANDALONE ANNUAL RESULT FOR NEULAND LABORATORIES LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	9510.77	11912	15585.8
Total Income	9531.53	12009.5	15711.2
Total Expenditure	8088.83	9198.9	10966.6
Other Income	20.77	97.48	125.44
Operating Profit	1442.7	2810.56	4744.65
Interest	134.94	130.67	139.97
PBDT	1307.76	2679.89	4604.68
Depreciation	490.36	527.76	596.99
Profit Before Tax	817.4	2152.13	4007.69
Tax	182.06	520.94	1011.73
Profit After Tax	635.34	1631.19	2995.96
Net Profit	635.34	1631.19	2995.96
Equity Capital	129	129.01	129.01
Face Value (IN RS)	10	10	10
Reserves	8218.35	9746.25	12628
Calculated EPS	49.25	126.44	232.23
Diluted Eps After Extraordinary Items	49.52	127.14	233.51
Diluted Eps Before Extraordinary Items	49.52	127.14	233.51

Consolidated Standalone

CONSOLIDATED PROFIT / LOSS FOR NEULAND LABORATORIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	936.91 Cr	951.08 Cr	1191.2 Cr	1558.58 Cr
Sales	881.25 Cr	887.38 Cr	1115.62 Cr	1447.48 Cr
Processing Charges / Service Income	36.92 Cr	35.95 Cr	45.28 Cr	68.19 Cr
Net Sales	936.91 Cr	951.08 Cr	1191.2 Cr	1558.58 Cr
Increase/Decrease in Stock	-1.24 Cr	-15.41 Cr	-9.51 Cr	-55.14 Cr
Raw Material Consumed	439.66 Cr	437.55 Cr	487.74 Cr	632.43 Cr
Opening Raw Materials	55 Cr	78.57 Cr	77.65 Cr	80.95 Cr
Purchases Raw Materials	463.23 Cr	436.63 Cr	491.04 Cr	650.45 Cr
Closing Raw Materials	78.57 Cr	77.65 Cr	80.95 Cr	98.97 Cr
Power & Fuel Cost	39.21 Cr	42.21 Cr	48.62 Cr	48.72 Cr
Electricity & Power	39.21 Cr	42.21 Cr	48.62 Cr	48.72 Cr
Employee Cost	149.74 Cr	182.47 Cr	201.79 Cr	257.06 Cr
Salaries, Wages & Bonus	132.9 Cr	162.06 Cr	181.22 Cr	233.71 Cr
Contributions to EPF & Pension Funds	5.69 Cr	7.27 Cr	8.09 Cr	9.43 Cr
Workmen and Staff Welfare Expenses	7.85 Cr	9.07 Cr	9.44 Cr	10.48 Cr
Other Manufacturing Expenses	81.08 Cr	89.16 Cr	86.94 Cr	107.79 Cr
Repairs and Maintenance	26.71 Cr	26.24 Cr	25.61 Cr	32.55 Cr
Packing Material Consumed	3.39 Cr	4.24 Cr	4.24 Cr	4.06 Cr
General and Administration Expenses	38.93 Cr	35.8 Cr	51.22 Cr	60.91 Cr
Rent , Rates & Taxes	18.15 Cr	10.2 Cr	5.5 Cr	8.99 Cr
Insurance	4.13 Cr	4.47 Cr	4.93 Cr	6.41 Cr
Professional and legal fees	8.99 Cr	10.82 Cr	24.55 Cr	24.02 Cr
Traveling and conveyance	6.69 Cr	9.26 Cr	14.47 Cr	18.6 Cr
Selling and Distribution Expenses	30.65 Cr	27.4 Cr	29.58 Cr	33.94 Cr
Advertisement & Sales Promotion	20.48 Cr	15.73 Cr	21.74 Cr	27.76 Cr
Freight and Forwarding	10.17 Cr	11.67 Cr	7.84 Cr	6.17 Cr
Miscellaneous Expenses	12.08 Cr	9.28 Cr	22.99 Cr	10.29 Cr
Provision for doubtful debts	3.85 Cr	56.79 Lk	4.67 Cr	0
Loss on disposal of fixed assets(net)	27.34 Lk	1.81 Cr	87.08 Lk	40.16 Lk
Loss on foreign exchange fluctuations	2.17 Cr	10.22 Lk	10.33 Cr	5.52 Lk
Total Expenditure	790.09 Cr	808.46 Cr	919.36 Cr	1095.99 Cr
Other Income	16.1 Cr	2.08 Cr	9.75 Cr	12.54 Cr
Interest Received	1.67 Cr	99.5 Lk	1.56 Cr	8.23 Cr
Profits on sale of Investments	13.09 Cr	0	0	0
Provision Written Back	0	0	3.78 Cr	4.04 Cr
Operating Profit	162.91 Cr	144.7 Cr	281.59 Cr	475.13 Cr
Interest	17.9 Cr	13.5 Cr	13.07 Cr	14 Cr
Interest on Term Loan	0	0	0	6.07 Cr
Bank Charges etc	6.08 Cr	3.96 Cr	4.78 Cr	2.92 Cr
PBDT	145.02 Cr	131.2 Cr	268.52 Cr	461.14 Cr
Depreciation	39.68 Cr	49.04 Cr	52.78 Cr	59.7 Cr
Profit Before Taxation & Exceptional Items	105.33 Cr	82.16 Cr	215.75 Cr	401.44 Cr
Profit Before Tax	105.33 Cr	82.16 Cr	215.75 Cr	401.44 Cr
Provision for Tax	24.7 Cr	18.34 Cr	52.23 Cr	101.36 Cr
Current Income Tax	12.56 Cr	20.43 Cr	50.44 Cr	99.67 Cr
Deferred Tax	12.15 Cr	-2.09 Cr	1.79 Cr	1.69 Cr
Profit After Tax	80.63 Cr	63.82 Cr	163.52 Cr	300.08 Cr
Consolidated Net Profit	80.63 Cr	63.82 Cr	163.52 Cr	300.08 Cr
Profit Balance B/F	170.09 Cr	248.16 Cr	308.13 Cr	465.24 Cr
Appropriations	250.72 Cr	311.98 Cr	471.65 Cr	765.31 Cr
Other Appropriation	0	3.85 Cr	6.41 Cr	12.83 Cr
Equity Dividend %	50	50	100	140
Earnings Per Share	62.85	49.74	127.45	233.89
Adjusted EPS	62.85	49.74	127.45	233.89

STANDALONE PROFIT / LOSS FOR NEULAND LABORATORIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	936.91 Cr	951.08 Cr	1191.2 Cr	1558.58 Cr
Sales	881.25 Cr	887.38 Cr	1115.62 Cr	1447.48 Cr
Processing Charges / Service Income	36.92 Cr	35.95 Cr	45.28 Cr	68.19 Cr
Net Sales	936.91 Cr	951.08 Cr	1191.2 Cr	1558.58 Cr
Increase/Decrease in Stock	-1.24 Cr	-15.41 Cr	-9.51 Cr	-55.14 Cr
Raw Material Consumed	439.66 Cr	437.55 Cr	487.74 Cr	632.43 Cr
Opening Raw Materials	55 Cr	78.57 Cr	77.65 Cr	80.95 Cr
Purchases Raw Materials	463.23 Cr	436.63 Cr	491.04 Cr	650.45 Cr
Closing Raw Materials	78.57 Cr	77.65 Cr	80.95 Cr	98.97 Cr
Power & Fuel Cost	39.21 Cr	42.21 Cr	48.62 Cr	48.72 Cr
Electricity & Power	39.21 Cr	42.21 Cr	48.62 Cr	48.72 Cr
Employee Cost	144.02 Cr	175.76 Cr	194.84 Cr	248.54 Cr
Salaries, Wages & Bonus	127.97 Cr	156.36 Cr	175.34 Cr	226.46 Cr
Contributions to EPF & Pension Funds	5.38 Cr	6.9 Cr	7.67 Cr	8.96 Cr
Workmen and Staff Welfare Expenses	7.38 Cr	8.55 Cr	8.79 Cr	9.69 Cr
Other Manufacturing Expenses	81.08 Cr	89.16 Cr	86.94 Cr	107.79 Cr
Repairs and Maintenance	26.71 Cr	26.24 Cr	25.61 Cr	32.55 Cr
Packing Material Consumed	3.39 Cr	4.24 Cr	4.24 Cr	4.06 Cr
General and Administration Expenses	37.42 Cr	34.5 Cr	48.24 Cr	57.05 Cr
Rent , Rates & Taxes	17.57 Cr	9.64 Cr	4.93 Cr	8.4 Cr
Insurance	3.95 Cr	4.26 Cr	4.73 Cr	6.21 Cr
Professional and legal fees	8.3 Cr	10.46 Cr	22.98 Cr	22.24 Cr
Traveling and conveyance	6.64 Cr	9.09 Cr	13.84 Cr	17.31 Cr
Selling and Distribution Expenses	38.41 Cr	36 Cr	40.25 Cr	47.24 Cr
Advertisement & Sales Promotion	28.24 Cr	24.33 Cr	32.41 Cr	41.06 Cr
Freight and Forwarding	10.17 Cr	11.67 Cr	7.84 Cr	6.17 Cr
Miscellaneous Expenses	11.93 Cr	9.12 Cr	22.77 Cr	10.04 Cr
Provision for doubtful debts	3.85 Cr	56.79 Lk	4.67 Cr	0
Loss on disposal of fixed assets(net)	27.34 Lk	1.81 Cr	87.08 Lk	40.16 Lk
Loss on foreign exchange fluctuations	2.17 Cr	10.22 Lk	10.33 Cr	5.52 Lk
Total Expenditure	790.47 Cr	808.88 Cr	919.89 Cr	1096.66 Cr
Other Income	16.09 Cr	2.08 Cr	9.75 Cr	12.54 Cr
Interest Received	1.67 Cr	99.49 Lk	1.56 Cr	8.23 Cr
Profits on sale of Investments	13.09 Cr	0	0	0
Provision Written Back	0	0	3.78 Cr	4.04 Cr
Operating Profit	162.54 Cr	144.27 Cr	281.06 Cr	474.47 Cr
Interest	17.9 Cr	13.49 Cr	13.07 Cr	14 Cr
Interest on Term Loan	0	0	0	6.07 Cr
Bank Charges etc	6.08 Cr	3.96 Cr	4.78 Cr	2.92 Cr
PBDT	144.64 Cr	130.78 Cr	267.99 Cr	460.47 Cr
Depreciation	39.68 Cr	49.04 Cr	52.78 Cr	59.7 Cr
Profit Before Taxation & Exceptional Items	104.96 Cr	81.74 Cr	215.21 Cr	400.77 Cr
Profit Before Tax	104.96 Cr	81.74 Cr	215.21 Cr	400.77 Cr
Provision for Tax	24.67 Cr	18.21 Cr	52.09 Cr	101.17 Cr
Current Income Tax	12.48 Cr	20.42 Cr	50.39 Cr	99.59 Cr
Deferred Tax	12.18 Cr	-2.22 Cr	1.7 Cr	1.59 Cr
Profit After Tax	80.29 Cr	63.53 Cr	163.12 Cr	299.6 Cr
Consolidated Net Profit	80.29 Cr	63.53 Cr	163.12 Cr	299.6 Cr
Profit Balance B/F	166.42 Cr	244.15 Cr	303.84 Cr	460.54 Cr
Appropriations	246.72 Cr	307.68 Cr	466.96 Cr	760.14 Cr
Other Appropriation	0	3.85 Cr	6.41 Cr	12.83 Cr
Equity Dividend %	50	50	100	140
Earnings Per Share	62.58	49.52	127.14	233.51
Adjusted EPS	62.58	49.52	127.14	233.51

Consolidated Standalone

CONSOLIDATED CASH FLOW FOR NEULAND LABORATORIES LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	105.33 Cr	82.16 Cr	215.75 Cr	401.44 Cr
Adjustment	40.08 Cr	64.5 Cr	76.05 Cr	62.08 Cr
Changes In working Capital	49.22 Cr	-67.58 Cr	-10.96 Cr	-90.73 Cr
Cash Flow after changes in Working Capital	194.64 Cr	79.07 Cr	280.84 Cr	372.78 Cr
Cash Flow from Operating Activities	189.36 Cr	58.58 Cr	237.21 Cr	261.18 Cr
Cash Flow from Investing Activities	-84.42 Cr	-93.71 Cr	-61.5 Cr	-149.69 Cr
Cash Flow from Financing Activitie	-113.66 Cr	37.72 Cr	-135.8 Cr	-69.28 Cr
Net Cash Inflow / Outflow	-8.72 Cr	2.59 Cr	39.92 Cr	42.21 Cr
Opening Cash & Cash Equivalents	11.2 Cr	2.44 Cr	5.09 Cr	45.42 Cr
Effect of Foreign Exchange Fluctuations	-4.55 Lk	6.18 Lk	40.69 Lk	-4.86 Lk
Closing Cash & Cash Equivalent	2.44 Cr	5.09 Cr	45.42 Cr	87.58 Cr

STANDALONE CASH FLOW FOR NEULAND LABORATORIES LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	104.96 Cr	81.74 Cr	215.21 Cr	400.77 Cr
Adjustment	40.17 Cr	64.37 Cr	76.06 Cr	62.07 Cr
Changes In working Capital	49.34 Cr	-66.99 Cr	-9.17 Cr	-91.22 Cr
Cash Flow after changes in Working Capital	194.47 Cr	79.12 Cr	282.1 Cr	371.63 Cr
Cash Flow from Operating Activities	189.28 Cr	58.6 Cr	238.53 Cr	260.06 Cr
Cash Flow from Investing Activities	-84.42 Cr	-93.72 Cr	-61.5 Cr	-149.67 Cr
Cash Flow from Financing Activitie	-113.66 Cr	37.72 Cr	-135.8 Cr	-69.28 Cr
Net Cash Inflow / Outflow	-8.8 Cr	2.6 Cr	41.24 Cr	41.11 Cr
Opening Cash & Cash Equivalents	9.92 Cr	1.12 Cr	3.72 Cr	44.96 Cr
Closing Cash & Cash Equivalent	1.12 Cr	3.72 Cr	44.96 Cr	86.07 Cr

Consolidated Standalone

CONSOLIDATED BALANCE SHEET FOR NEULAND LABORATORIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	12.9 Cr	12.9 Cr	12.9 Cr	12.9 Cr
Equity - Authorised	44 Cr	44 Cr	44 Cr	44 Cr
Equity - Issued	13.02 Cr	13.02 Cr	13.02 Cr	13.02 Cr
Equity Paid Up	12.83 Cr	12.83 Cr	12.83 Cr	12.83 Cr
Equity Shares Forfeited	7.06 Lk	7.06 Lk	7.06 Lk	7.06 Lk
Face Value	10	10	10	10
Total Reserves	773.56 Cr	827.6 Cr	981.2 Cr	1269.8 Cr
Securities Premium	497.77 Cr	497.77 Cr	497.77 Cr	497.77 Cr
Capital Reserves	3.32 Lk	3.32 Lk	3.32 Lk	3.32 Lk
Profit & Loss Account Balance	248.16 Cr	308.13 Cr	465.23 Cr	752.48 Cr
General Reserves	27.9 Cr	27.9 Cr	27.9 Cr	27.9 Cr
Reserve excluding Revaluation Reserve	772.72 Cr	826.76 Cr	980.36 Cr	1268.97 Cr
Revaluation reserve	83.89 Lk	83.89 Lk	83.89 Lk	83.89 Lk
Shareholder's Funds	786.46 Cr	840.5 Cr	994.1 Cr	1282.7 Cr
Secured Loans	88.13 Cr	104.25 Cr	74.25 Cr	44.92 Cr
Term Loans - Banks	110.06 Cr	134.52 Cr	105.76 Cr	71.91 Cr
Deferred Tax Assets / Liabilities	59.76 Cr	56.7 Cr	58.3 Cr	60.44 Cr
Deferred Tax Assets	9.66 Cr	16.73 Cr	13.52 Cr	12.71 Cr
Deferred Tax Liability	69.42 Cr	73.43 Cr	71.82 Cr	73.15 Cr
Other Long Term Liabilities	12.49 Cr	6.97 Cr	3.88 Cr	9.2 Cr
Long Term Provisions	9.44 Cr	11.91 Cr	10.29 Cr	7.61 Cr
Total Non-Current Liabilities	169.82 Cr	179.83 Cr	146.71 Cr	122.17 Cr
Trade Payables	152.14 Cr	112.27 Cr	171 Cr	191.96 Cr
Sundry Creditors	152.14 Cr	112.27 Cr	171 Cr	191.96 Cr
Other Current Liabilities	158.75 Cr	157.46 Cr	244.87 Cr	234.01 Cr
Advances received from customers	63.61 Cr	63.22 Cr	136.56 Cr	81.17 Cr
Interest Accrued But Not Due	39.6 Lk	33.21 Lk	24.58 Lk	18.83 Lk
Short Term Borrowings	56.98 Cr	92.21 Cr	11.16 Cr	0
Secured ST Loans repayable on Demands	56.98 Cr	92.21 Cr	11.16 Cr	0
Working Capital Loans- Sec	56.98 Cr	92.21 Cr	11.16 Cr	0
Short Term Provisions	64.26 Lk	1.21 Cr	11.93 Cr	1.72 Cr
Provision for Tax	0	0	10.4 Cr	8.14 Lk
Total Current Liabilities	368.51 Cr	363.16 Cr	438.96 Cr	427.68 Cr
Total Liabilities	1324.79 Cr	1383.49 Cr	1579.76 Cr	1832.56 Cr
Gross Block	826.48 Cr	919.62 Cr	953.26 Cr	1072.98 Cr
Less: Accumulated Depreciation	129.54 Cr	171.92 Cr	215.07 Cr	268.34 Cr
Net Block	696.94 Cr	747.7 Cr	738.19 Cr	804.64 Cr
Capital Work in Progress	17.25 Cr	20.46 Cr	40.57 Cr	45.89 Cr
Non Current Investments	19.35 Cr	20.16 Cr	52.49 Lk	1.28 Cr
Long Term Investment	19.35 Cr	20.16 Cr	52.49 Lk	1.28 Cr
Quoted	19.28 Lk	25.02 Lk	27.77 Lk	0
Unquoted	19.15 Cr	19.91 Cr	24.72 Lk	1.28 Cr
Long Term Loans & Advances	41.67 Cr	12.4 Cr	20.24 Cr	40.47 Cr
Other Non Current Assets	0	0	0	17.44 Lk
Total Non-Current Assets	775.2 Cr	800.71 Cr	818.87 Cr	911.48 Cr
Currents Investments	6.46 Cr	3.38 Cr	0	0
Unquoted	19.15 Cr	19.91 Cr	24.72 Lk	1.28 Cr
Inventories	247.61 Cr	265.21 Cr	279.23 Cr	350.42 Cr
Raw Materials	78.57 Cr	77.65 Cr	80.95 Cr	98.97 Cr
Work-in Progress	107.63 Cr	119.41 Cr	117.89 Cr	147.7 Cr
Finished Goods	49.03 Cr	52.67 Cr	63.7 Cr	89.03 Cr
Stores and Spare	12.37 Cr	15.48 Cr	16.7 Cr	14.72 Cr
Sundry Debtors	217.73 Cr	234.33 Cr	361.77 Cr	373.53 Cr
Debtors more than Six months	0	4.13 Cr	3.7 Cr	2.88 Cr
Debtors Others	221.11 Cr	234.4 Cr	361.59 Cr	371.28 Cr
Cash and Bank	19.4 Cr	20.36 Cr	59.1 Cr	116.8 Cr
Cash in hand	3.18 Lk	2.1 Lk	2.01 Lk	4.21 Lk
Balances at Bank	19.37 Cr	20.34 Cr	59.08 Cr	116.75 Cr
Other Current Assets	11.77 Cr	11.52 Cr	13.7 Cr	18.3 Cr
Interest accrued on Investments	16.56 Lk	7.28 Lk	9.02 Lk	42.38 Lk
Prepaid Expenses	7.17 Cr	7.42 Cr	10.54 Cr	11.14 Cr
Short Term Loans and Advances	46.62 Cr	47.98 Cr	47.09 Cr	62.03 Cr
Advances recoverable in cash or in kind	20.01 Cr	32.99 Cr	24.73 Cr	18.68 Cr
Total Current Assets	549.59 Cr	582.78 Cr	760.89 Cr	921.08 Cr
Net Current Assets (Including Current Investments)	181.08 Cr	219.62 Cr	321.94 Cr	493.4 Cr
Total Assets	1324.79 Cr	1383.49 Cr	1579.76 Cr	1832.56 Cr
Contingent Liabilities	104.67 Cr	74.68 Cr	91.21 Cr	82.56 Cr
Total Debt	170.18 Cr	230.95 Cr	121.51 Cr	82.51 Cr
Book Value	612.28	654.4	0	999.07
Adjusted Book Value	612.28	654.4	774.12	999.07

STANDALONE BALANCE SHEET FOR NEULAND LABORATORIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	12.9 Cr	12.9 Cr	12.9 Cr	12.9 Cr
Equity - Authorised	44 Cr	44 Cr	44 Cr	44 Cr
Equity - Issued	13.02 Cr	13.02 Cr	13.02 Cr	13.02 Cr
Equity Paid Up	12.83 Cr	12.83 Cr	12.83 Cr	12.83 Cr
Equity Shares Forfeited	7.06 Lk	7.06 Lk	7.06 Lk	7.06 Lk
Face Value	10	10	10	10
Total Reserves	768.98 Cr	822.67 Cr	975.46 Cr	1263.64 Cr
Securities Premium	497.77 Cr	497.77 Cr	497.77 Cr	497.77 Cr
Capital Reserves	3.32 Lk	3.32 Lk	3.32 Lk	3.32 Lk
Profit & Loss Account Balance	244.15 Cr	303.84 Cr	460.54 Cr	747.31 Cr
General Reserves	27.9 Cr	27.9 Cr	27.9 Cr	27.9 Cr
Reserve excluding Revaluation Reserve	768.14 Cr	821.84 Cr	974.62 Cr	1262.8 Cr
Revaluation reserve	83.89 Lk	83.89 Lk	83.89 Lk	83.89 Lk
Shareholder's Funds	781.88 Cr	835.57 Cr	988.36 Cr	1276.54 Cr
Secured Loans	88.13 Cr	104.25 Cr	74.25 Cr	44.92 Cr
Term Loans - Banks	110.06 Cr	134.52 Cr	105.76 Cr	71.91 Cr
Deferred Tax Assets / Liabilities	59 Cr	55.78 Cr	57.3 Cr	59.34 Cr
Deferred Tax Assets	10.42 Cr	16.73 Cr	13.52 Cr	12.71 Cr
Deferred Tax Liability	69.42 Cr	72.51 Cr	70.82 Cr	72.05 Cr
Other Long Term Liabilities	12.45 Cr	6.94 Cr	3.85 Cr	9.2 Cr
Long Term Provisions	9.1 Cr	11.45 Cr	9.83 Cr	7.13 Cr
Total Non-Current Liabilities	168.68 Cr	178.42 Cr	145.22 Cr	120.59 Cr
Trade Payables	156.75 Cr	117.54 Cr	177.99 Cr	198.54 Cr
Sundry Creditors	156.75 Cr	117.54 Cr	177.99 Cr	198.54 Cr
Other Current Liabilities	158.59 Cr	157.16 Cr	244.71 Cr	233.62 Cr
Advances received from customers	63.61 Cr	63.22 Cr	136.56 Cr	81.17 Cr
Interest Accrued But Not Due	39.6 Lk	33.21 Lk	24.58 Lk	18.83 Lk
Short Term Borrowings	56.98 Cr	92.21 Cr	11.16 Cr	0
Secured ST Loans repayable on Demands	56.98 Cr	92.21 Cr	11.16 Cr	0
Working Capital Loans- Sec	56.98 Cr	92.21 Cr	11.16 Cr	0
Short Term Provisions	64.26 Lk	1.21 Cr	11.89 Cr	1.64 Cr
Provision for Tax	0	0	10.37 Cr	0
Total Current Liabilities	372.96 Cr	368.12 Cr	445.75 Cr	433.8 Cr
Total Liabilities	1323.52 Cr	1382.12 Cr	1579.34 Cr	1830.93 Cr
Gross Block	826.46 Cr	919.6 Cr	953.24 Cr	1075.84 Cr
Less: Accumulated Depreciation	129.53 Cr	171.9 Cr	215.05 Cr	271.22 Cr
Net Block	696.92 Cr	747.7 Cr	738.19 Cr	804.63 Cr
Capital Work in Progress	17.25 Cr	20.46 Cr	40.57 Cr	45.89 Cr
Non Current Investments	19.5 Cr	20.31 Cr	68.31 Lk	1.44 Cr
Long Term Investment	19.5 Cr	20.31 Cr	68.31 Lk	1.44 Cr
Quoted	19.27 Lk	25.02 Lk	27.77 Lk	0
Unquoted	19.31 Cr	20.06 Cr	40.54 Lk	1.44 Cr
Long Term Loans & Advances	41.66 Cr	12.42 Cr	20.21 Cr	40.31 Cr
Other Non Current Assets	0	0	0	16.53 Lk
Total Non-Current Assets	775.34 Cr	800.89 Cr	819 Cr	911.46 Cr
Currents Investments	6.46 Cr	3.38 Cr	0	0
Unquoted	19.31 Cr	20.06 Cr	40.54 Lk	1.44 Cr
Inventories	247.61 Cr	265.21 Cr	279.23 Cr	350.42 Cr
Raw Materials	78.57 Cr	77.65 Cr	80.95 Cr	98.97 Cr
Work-in Progress	107.63 Cr	119.41 Cr	117.89 Cr	147.7 Cr
Finished Goods	49.03 Cr	52.67 Cr	63.7 Cr	89.03 Cr
Stores and Spare	12.37 Cr	15.48 Cr	16.7 Cr	14.72 Cr
Sundry Debtors	217.73 Cr	234.33 Cr	361.77 Cr	373.53 Cr
Debtors more than Six months	0	4.13 Cr	3.7 Cr	2.88 Cr
Debtors Others	221.11 Cr	234.4 Cr	361.59 Cr	371.28 Cr
Cash and Bank	18.08 Cr	18.99 Cr	58.65 Cr	115.29 Cr
Cash in hand	3.18 Lk	2.1 Lk	2.01 Lk	4.21 Lk
Balances at Bank	18.05 Cr	18.97 Cr	58.63 Cr	115.24 Cr
Other Current Assets	11.69 Cr	11.39 Cr	13.66 Cr	18.27 Cr
Interest accrued on Investments	16.56 Lk	7.28 Lk	9.02 Lk	42.38 Lk
Prepaid Expenses	7.09 Cr	7.29 Cr	10.5 Cr	11.11 Cr
Short Term Loans and Advances	46.62 Cr	47.94 Cr	47.03 Cr	61.96 Cr
Advances recoverable in cash or in kind	20 Cr	20.84 Cr	24.73 Cr	18.68 Cr
Total Current Assets	548.18 Cr	581.23 Cr	760.34 Cr	919.47 Cr
Net Current Assets (Including Current Investments)	175.22 Cr	213.11 Cr	314.59 Cr	485.67 Cr
Total Assets	1323.52 Cr	1382.12 Cr	1579.34 Cr	1830.93 Cr
Contingent Liabilities	104.67 Cr	74.68 Cr	91.21 Cr	82.56 Cr
Total Debt	170.18 Cr	230.95 Cr	121.51 Cr	82.51 Cr
Book Value	608.71	650.56	0	994.26
Adjusted Book Value	608.71	650.56	769.65	994.26

Consolidated Standalone

FINANCIAL RATIOS (CONSOLIDATED) FOR NEULAND LABORATORIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	62.85	49.74	127.45	233.89
CEPS(Rs)	93.78	87.97	168.59	280.42
DPS(Rs)	5	5	10	14
Book NAV/Share(Rs)	612.28	654.4	774.12	999.07
Tax Rate(%)	23.45	22.32	24.21	25.25
Margin Ratios
Core EBITDA Margin(%)	15.67	15	22.82	29.68
EBIT Margin(%)	13.15	10.06	19.21	26.65
Pre Tax Margin(%)	11.24	8.64	18.11	25.76
PAT Margin (%)	8.61	6.71	13.73	19.25
Cash Profit Margin (%)	12.84	11.87	18.16	23.08
Performance Ratios
ROA(%)	6.31	4.71	11.04	17.59
ROE(%)	10.79	7.85	17.84	26.38
ROCE(%)	12.81	9.44	20.94	33.51
Asset Turnover(x)	0.73	0.7	0.8	0.91
Sales/Fixed Asset(x)	1.22	1.09	1.28	1.54
Working Capital/Sales(x)	5.17	4.33	3.7	3.16
Efficiency Ratios
Fixed Capital/Sales(x)	0.82	0.92	0.78	0.65
Receivable days	79.4	86.74	91.33	86.1
Inventory Days	91	98.4	83.41	73.73
Payable days	62.06	114.31	110.05	114.75
Valuation Parameters
PER(x)	33.22	20.64	14.12	26.86
PCE(x)	22.27	11.67	10.67	22.4
Price/Book(x)	3.41	1.57	2.32	6.29
Yield(%)	0.24	0.49	0.56	0.22
EV/Net Sales(x)	3.02	1.61	1.99	5.15
EV/Core EBITDA(x)	17.37	10.56	8.42	16.89
EV/EBIT(x)	22.96	15.97	10.36	19.32
EV/CE(x)	2.14	1.1	1.5	5.88
M Cap / Sales	2.86	1.38	1.94	5.17
Growth Ratio
Net Sales Growth(%)	22.84	1.51	25.25	30.84
Core EBITDA Growth(%)	54.02	-11.18	94.61	68.73
EBIT Growth(%)	65.42	-22.38	139.2	81.56
PAT Growth(%)	397.4	-20.85	156.21	83.51
EPS Growth(%)	397.4	-20.85	156.21	83.51
Financial Stability Ratios
Total Debt/Equity(x)	0.22	0.28	0.12	0.06
Current Ratio(x)	1.49	1.6	1.73	2.15
Quick Ratio(x)	0.82	0.87	1.1	1.33
Interest Cover(x)	6.89	7.09	17.51	29.68
Total Debt/Mcap(x)	0.06	0.18	0.05	0.01

FINANCIAL RATIOS (STANDALONE) FOR NEULAND LABORATORIES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	62.58	49.52	127.14	233.51
CEPS(Rs)	93.51	87.74	168.28	280.05
DPS(Rs)	5	5	10	14
Book NAV/Share(Rs)	608.71	650.56	769.65	994.26
Tax Rate(%)	23.5	22.27	24.21	25.24
Margin Ratios
Core EBITDA Margin(%)	15.63	14.95	22.78	29.64
EBIT Margin(%)	13.11	10.01	19.16	26.61
Pre Tax Margin(%)	11.2	8.59	18.07	25.71
PAT Margin (%)	8.57	6.68	13.69	19.22
Cash Profit Margin (%)	12.81	11.84	18.12	23.05
Performance Ratios
ROA(%)	6.29	4.7	11.02	17.57
ROE(%)	10.81	7.86	17.9	26.48
ROCE(%)	12.83	9.44	20.99	33.62
Asset Turnover(x)	0.73	0.7	0.8	0.91
Sales/Fixed Asset(x)	1.22	1.09	1.28	1.54
Working Capital/Sales(x)	5.35	4.46	3.79	3.21
Efficiency Ratios
Fixed Capital/Sales(x)	0.82	0.92	0.78	0.65
Receivable days	79.4	86.74	91.33	86.1
Inventory Days	91	98.4	83.41	73.73
Payable days	64	118.58	114.73	119.04
Valuation Parameters
PER(x)	33.36	20.73	14.15	26.9
PCE(x)	22.33	11.7	10.69	22.43
Price/Book(x)	3.43	1.58	2.34	6.32
Yield(%)	0.24	0.49	0.56	0.22
EV/Net Sales(x)	3.02	1.61	1.99	5.15
EV/Core EBITDA(x)	17.42	10.6	8.44	16.92
EV/EBIT(x)	23.04	16.06	10.39	19.35
EV/CE(x)	2.14	1.11	1.5	5.91
M Cap / Sales	2.86	1.38	1.94	5.17
Growth Ratio
Net Sales Growth(%)	22.84	1.51	25.25	30.84
Core EBITDA Growth(%)	54.29	-11.24	94.81	68.82
EBIT Growth(%)	65.88	-22.49	139.7	81.69
PAT Growth(%)	405.63	-20.87	156.75	83.67
EPS Growth(%)	405.63	-20.87	156.75	83.67
Financial Stability Ratios
Total Debt/Equity(x)	0.22	0.28	0.12	0.06
Current Ratio(x)	1.47	1.58	1.71	2.12
Quick Ratio(x)	0.81	0.86	1.08	1.31
Interest Cover(x)	6.86	7.06	17.47	29.63
Total Debt/Mcap(x)	0.06	0.18	0.05	0.01

SHARE HOLDING PATTERN FOR NEULAND LABORATORIES LIMITED

Date	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters %	36.22	36.22	36.14	36.14	36.03	35.97	32.80	32.74	32.72	32.64
FII %	17.37	17.68	17.70	18.14	20.19	21.57	22.69	24.43	25.72	26.46
DII %	5.65	5.78	5.75	6.11	5.19	5.05	4.19	2.66	2.32	1.94
Public %	39.94	39.08	39.15	38.23	36.62	35.07	38.08	35.88	34.76	34.11

PEER COMPARISON FOR NEULAND LABORATORIES LIMITED

No.	Name
1	AMBALAL SARABHAI ENTERPRISES LTD
2	Cipla Limited
3	Dr. Reddy's Laboratories Limited
4	Procter & Gamble Health Limited
5	J.K.PHARMACHEM LTD
6	Lupin Limited
7	Lyka Labs Limited
8	MESCO PHARMACEUTICALS LTD
9	Morepen Laboratories Limited
10	Piramal Enterprises Limited
11	Torrent Pharmaceuticals Limited
12	Abbott India Limited
13	GlaxoSmithKline Pharmaceuticals Limited
14	Sanofi India Limited
15	Pfizer Limited
16	Bliss GVS Pharma Limited
17	Alembic Limited
18	Unichem Laboratories Limited
19	AstraZeneca Pharma India Limited
20	GUJARAT THEMIS BIOSYN LTD
21	JB Chemicals & Pharmaceuticals Limited
22	TTK Healthcare Limited
23	Jagsonpal Pharmaceuticals Limited
24	Gufic Biosciences Limited
25	Sequent Scientific Limited
26	Albert David Limited
27	IOL Chemicals and Pharmaceuticals Limited
28	Wanbury Limited
29	Kopran Limited
30	Aarti Drugs Limited
31	Orchid Pharma Limited
32	Biofil Chemicals & Pharmaceuticals Limited
33	Marksans Pharma Limited
34	IPCA Laboratories Limited
35	Kilitch Drugs (India) Limited
36	Krebs Biochemicals and Industries Limited
37	Neuland Laboratories Limited
38	Ind-Swift Limited
39	Hester Biosciences Limited
40	Parenteral Drugs (India) Limited
41	Sun Pharmaceutical Industries Limited
42	Hikal Limited
43	Caplin Point Laboratories Limited
44	Aurobindo Pharma Limited
45	Natco Pharma Limited
46	Bal Pharma Limited
47	BDH INDUSTRIES LTD
48	Venus Remedies Limited
49	Jubilant Pharmova Limited
50	Themis Medicare Limited

CORPORATE ACTIONS FOR NEULAND LABORATORIES

Exchange Date	Purpose	Book Closure Dates
BSE 17-Oct-2024	Board Meeting - Quarterly Results	06-Nov-2024
BSE 18-Jul-2024	Board Meeting - Quarterly Results	01-Aug-2024
BSE 10-May-2024	Book Closure - Rs.14.0000 per share(140%)Final Dividend & A.G.M.	13-Jul-2024 15-Jul-2024
BSE 10-May-2024	AGM - Rs.14.0000 per share(140%)Final Dividend & A.G.M.	15-Jul-2024 15-Jul-2024
BSE 10-May-2024	Dividend - Rs.14.0000 per share(140%)Final Dividend
BSE 23-Apr-2024	Board Meeting - Audited Results & Final Dividend	10-May-2024
BSE 25-Jan-2024	Board Meeting - Quarterly Results	08-Feb-2024
BSE 11-Oct-2023	Board Meeting - Quarterly Results	07-Nov-2023
BSE 11-Jul-2023	Dividend - Rs.10.0000 per share(100%)Final Dividend
BSE 10-Jul-2023	Board Meeting - Quarterly Results	03-Aug-2023
BSE 11-May-2023	Book Closure - Rs.10.0000 per share(100%)Final Dividend & A.G.M.	12-Jul-2023 14-Jul-2023
BSE 11-May-2023	AGM - Rs.10.0000 per share(100%)Final Dividend & A.G.M.	27-Jul-2023 14-Jul-2023
BSE 17-Apr-2023	Board Meeting - Audited Results & Final Dividend	11-May-2023
BSE 20-Jan-2023	Board Meeting - Quarterly Results	13-Feb-2023
BSE 14-Oct-2022	Board Meeting - Quarterly Results	10-Nov-2022
BSE 11-Jul-2022	Board Meeting - Quarterly Results	03-Aug-2022
BSE 10-May-2022	Dividend - Rs.5.0000 per share(50%)Final Dividend
BSE 18-Apr-2022	Board Meeting - Final Dividend & Audited Results	10-May-2022
BSE 07-Jan-2022	Board Meeting - Quarterly Results	01-Feb-2022
BSE 20-Oct-2021	Board Meeting - Quarterly Results	29-Oct-2021

CORPORATE ANNOUNCEMENTS FOR NEULAND LABORATORIES

Exchange Date	Category File	Description
BSE 28-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Q2 FY25 Earnings Call Intimation
BSE 24-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Copy of Newspaper publication
BSE 18-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Issue of Letter of Confirmation in lieu of Share Certificate(s) lost / misplaced
BSE 17-Oct-2024	Intimation FILE	Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30 2024 NEULAND LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended September 30 2024
BSE 16-Oct-2024	General Announcements FILE	Clarification On Recent News In The Media / Social Media Clarification on recent news in the media / social media
BSE 15-Oct-2024	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Certificate under Reg. 74(5) of SEBI (DP) Regulations 2018
BSE 10-Oct-2024	General Announcements FILE	Disclosure Under Regulation 30 Of The SEBI Listing Regulations - Update On Pending Litigation Disclosure under Regulation 30 of SEBI Listing Regulations - Update on pending Litigation
BSE 09-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of Loss of Share Certificate(s)
BSE 26-Sep-2024	Intimation FILE	Closure of Trading Window Closure of Trading Window
BSE 18-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation about Schedule of Analyst / Institutional Investor Meeting on September 23 2024
BSE 30-Aug-2024	General Announcements FILE	Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 Disclosure under Regulation 30 of SEBI Listing Regulations
BSE 30-Aug-2024	General Announcements FILE	Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 Disclosure under Regulation 30 of SEBI Listing Regulations
BSE 23-Aug-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Issue of Letter of Confirmation in lieu of Share Certificate(s) reported lost / misplaced
BSE 19-Aug-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of Loss of Share Certificate(s)
BSE 12-Aug-2024	General FILE	Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Malabar India Fund Ltd
BSE 10-Aug-2024	General FILE	Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Malabar India Fund Ltd
BSE 06-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Earnings Call Transcript Transcript of the Earnings Call conducted on August 1 2024
BSE 02-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Copy of Newspaper Publication
BSE 01-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Audio Recording of the Earnings call conducted on August 1 2024
BSE 01-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Investor Presentation Investors/Analysts Presentation on the Financial Results of the Company for the quarter ended June 30 2024
BSE 01-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release Press Release on the Financial Results of the Company for the quarter ended June 30 2024
BSE 01-Aug-2024	General Announcements FILE	Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
BSE 01-Aug-2024	Outcome FILE	Board Meeting Outcome for Unaudited Financial Results For Quarter Ended June 30 2024 Unaudited Financial results for quarter ended June 30 2024
BSE 01-Aug-2024	Outcome FILE	Unaudited Financial Results For Quarter Ended June 30 2024 Unaudited Financial results for quarter ended June 30 2024
BSE 31-Jul-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report Voting results Scrutinizer report and proceedings of 40th Annual General Meeting held on July 31 2024
BSE 31-Jul-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Outcome of AGM Voting results Scrutinizer report and proceedings of 40th Annual General Meeting held on July 31 2024
BSE 24-Jul-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Earnings call Intimation Q1 FY25
BSE 17-Jul-2024	Intimation FILE	Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter Ended June 30 2024 NEULAND LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2024 inter alia to consider and approve the unaudited financial results of the Company for the Quarter ended June 30 2024
BSE 15-Jul-2024	General Announcements FILE	Business Responsibility and Sustainability Reporting (BRSR) Submission of revised Business Responsibility and Sustainability Report for FY 2023-24
BSE 15-Jul-2024	General Announcements FILE	Reg. 34 (1) Annual Report. Revised Integrated Annual Report for FY 2023-24

INSIDER TRADING FOR NEULAND LABORATORIES

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 04-Dec-2023 04-Dec-2023	Sell Market	500 @ 0.00 (0.00 %)	Nirupama Sundar
BSE 18-Aug-2023 18-Aug-2023	Sell Gift	33,500 @ 0.00 (0.26 %)	Davuluri Ramamohan Rao
BSE 18-Aug-2023 18-Aug-2023	Buy Gift	33,500 @ 0.00 (0.26 %)	Davuluri Saharsh Rao
BSE 17-Aug-2022 25-Aug-2022	Buy Market	900 @ 0.00 (0.00 %)	Nirupama Sundar
BSE 21-Mar-2022 21-Mar-2022	Sell Gift	77,634 @ 0.00 (0.61 %)	Davuluri Rohini Niveditha Rao

BULK BLOCK DEALS FOR NEULAND LABORATORIES LIMITED

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 26-Jun-2024	Sell BULK	130,000 @ 7400.00	MALABAR INDIA FUND LIMITED
BSE 26-Jun-2024	Buy BULK	130,000 @ 7400.00	SMALLCAP WORLD FUND INC
BSE 26-Jun-2024	Buy BLOCK	130,000 @ 7400.00	SMALLCAP WORLD FUND INC
BSE 26-Jun-2024	Sell BLOCK	130,000 @ 7400.00	MALABAR INDIA FUND LIMITED
BSE 08-Dec-2023	Sell BULK	400,000 @ 5012.45	RAMAMOHAN RAO DAVULURI

DIVIDEND BY NEULAND LABORATORIES LIMITED

Ex Dividend Date	Dividend Type	Dividend
12-Jul-2024	DIVIDEND	14
11-Jul-2023	DIVIDEND	10
14-Jul-2022	DIVIDEND	5
29-Jun-2021	DIVIDEND	3
10-Nov-2020	INTERIM DIVIDEND	2

SPLIT / BONUS BY NEULAND LABORATORIES LIMITED

No Split / Bonus details found

Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed

Facebook

Twitter

To TOP

Neuland Laboratories Limited

Neuland Laboratories share price

CONSOLIDATED QUARTERLY RESULT FOR NEULAND LABORATORIES LIMITED

STANDALONE QUARTERLY RESULT FOR NEULAND LABORATORIES LIMITED

CONSOLIDATED ANNUAL RESULT FOR NEULAND LABORATORIES LIMITED

STANDALONE ANNUAL RESULT FOR NEULAND LABORATORIES LIMITED

CONSOLIDATED PROFIT / LOSS FOR NEULAND LABORATORIES LIMITED

STANDALONE PROFIT / LOSS FOR NEULAND LABORATORIES LIMITED

CONSOLIDATED CASH FLOW FOR NEULAND LABORATORIES LIMITED

STANDALONE CASH FLOW FOR NEULAND LABORATORIES LIMITED

CONSOLIDATED BALANCE SHEET FOR NEULAND LABORATORIES LIMITED

STANDALONE BALANCE SHEET FOR NEULAND LABORATORIES LIMITED

FINANCIAL RATIOS (CONSOLIDATED) FOR NEULAND LABORATORIES LIMITED

FINANCIAL RATIOS (STANDALONE) FOR NEULAND LABORATORIES LIMITED

SHARE HOLDING PATTERN FOR NEULAND LABORATORIES LIMITED

PEER COMPARISON FOR NEULAND LABORATORIES LIMITED

CORPORATE ACTIONS FOR NEULAND LABORATORIES

CORPORATE ANNOUNCEMENTS FOR NEULAND LABORATORIES

INSIDER TRADING FOR NEULAND LABORATORIES

BULK BLOCK DEALS FOR NEULAND LABORATORIES LIMITED

DIVIDEND BY NEULAND LABORATORIES LIMITED

SPLIT / BONUS BY NEULAND LABORATORIES LIMITED